Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NY65
UPID:
TBA8_HUMAN
Alternative names:
Alpha-tubulin 8; Tubulin alpha chain-like 2
Alternative UPACC:
Q9NY65; B2RCX2; B3KPW9; B4DWG3; Q2M3N4
Background:
Tubulin alpha-8 chain, also known as Alpha-tubulin 8 and Tubulin alpha chain-like 2, plays a pivotal role in cell structure and function as the major constituent of microtubules. These microtubules are essential for various cellular processes, including cell division, intracellular transport, and maintenance of cell shape. The dynamic assembly of tubulin into microtubules involves the addition of GTP-tubulin dimers, facilitated by the GTPase activity of alpha-tubulin.
Therapeutic significance:
The Tubulin alpha-8 chain's involvement in Macrothrombocytopenia, an autosomal dominant blood disorder, highlights its potential as a target for therapeutic intervention. Understanding the role of Tubulin alpha-8 chain could open doors to potential therapeutic strategies, offering hope for individuals affected by this and possibly other related disorders.